Preclinical Assessment of Gene Therapy for Ventricular Arrhythmia

室性心律失常基因治疗的临床前评估

• 批准号: nhmrc : 1128864
• 负责人: Dr Eddy Kizana
• 金额: $ 54.66万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-assessment-gene-ventricular-arrhythmia/948286
• 关键词: Preclinical; Assessment; Gene; Therapy; Ventricular

Up to 10% of patients are at risk of sudden death following myocardial infarction. Current treatment and preventative initiatives have their limits and are not without risk. In this proposal we will continue to develop an exciting new treatment approach using gene therapy technology. We will attempt to overcome some of the barriers for human application of this technology and pave the way for early phase clinical trials.

高达10%的患者有心肌梗死后猝死的危险。目前的治疗和预防措施有其局限性，并不是没有风险。在这个提议中，我们将继续开发一种令人兴奋的新的治疗方法，使用基因治疗技术。我们将努力克服人类应用这项技术的一些障碍，并为早期临床试验铺平道路。